Post-epidemic eosinophilia myalgia syndrome associated with L-Tryptophan
Ontology highlight
ABSTRACT: Eosinophilia–myalgia syndrome (EMS) is characterized by subacute onset of myalgias and peripheral eosinophilia, followed by chronic neuropathy and skin induration. The EMS epidemic in 1989 was linked to L-tryptophan consumption originating from a single source. Following the Food and Drug Administration (FDA) ban on the sale of L-tryptophan, the incidence of EMS declined rapidly. Moreover, no new cases have been published since the FDA ban was lifted in 2005. We report the clinical, histopathological and immunogenetic features of a new case of L-tryptophan-associated EMS along with evidence of activated transforming growth factor-ß and interleukin-4 signaling in the lesional skin. 6 samples were analyzed to include EMS patient and two replicates along with three normal controls
ORGANISM(S): Homo sapiens
SUBMITTER: Tammara Wood
PROVIDER: E-GEOD-26934 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA